Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer

被引：87
|
作者：
Hamilton, Chad A. [1 ]
Maxwell, G. Larry [1 ]
Chemofsky, Mildred R. [1 ]
Bernstein, Sarah A. [1 ]
Farley, John H. [1 ]
Rose, G. Scott [1 ]
机构：
[1] Walter Reed Army Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Washington, DC 20307 USA
来源：
GYNECOLOGIC ONCOLOGY | 2008年 / 111卷 / 03期
关键词：
Bevacizumab; Intraperitoneal; Ovarian cancer; Ascites; Palliation;
D O I：
10.1016/j.ygyno.2008.04.028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background. Malignant ascites often has a profound impact on the quality of life of patients with refractory ovarian cancer. Current treatments, including dietary, medical, and procedural are often temporary and unsatisfactory options in patients approaching the end of life. Case. We present a case of an 88 year-old receiving home hospice care with refractory ovarian cancer and severe symptomatic ascites. We performed a paracentesis and treated her with intraperitoneal bevacizumab with dramatic improvement in her ascites and the quality of her final weeks of life. Conclusion. Intraperitoneal bevacizumab may be a useful 1001 in the palliation of malignant ascites and is worthy of further study. Published by Elsevier Inc.
引用
收藏
页码：530 / 532
页数：3
相关论文
共 50 条
  • [1] A pilot study of intraperitoneal bevacizumab for the palliation of malignant ascites
    Jones, Joanna M. D.
    Hardy, Janet R.
    Munster, David J.
    Shannon, Catherine M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (03) : 261 - 262
  • [2] INTRAPERITONEAL BEVACIZUMAB AND PACLIATAXEL IV IN PATIENTS WITH METASTATIC OVARIAN CANCER AND REFRACTORY MALIGNANT ASCITES: SAFETY AND TOLERABILITY
    Lugini, A.
    Del Matto, N.
    Pace, R.
    Morandi, M. G.
    Rauco, A. M.
    De Santis, G.
    Domini, P.
    Capparella, V
    ANNALS OF ONCOLOGY, 2009, 20
  • [3] Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites
    Kou, Furong
    Gong, Jifang
    Li, Yan
    Li, Jian
    Zhang, Xiaotian
    Li, Jie
    Shen, Lin
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2021, 49 (02)
  • [4] Intraperitoneal nivolumab in a patient with pancreatic cancer and refractory malignant ascites
    Wang, Sing-Ting
    Chiu, Chang-Fang
    Bai, Hui-Jen
    Bai, Li-Yuan
    EUROPEAN JOURNAL OF CANCER, 2021, 148 : 48 - 50
  • [5] Intraperitoneal bevacizumab (Bev) for control of refractory malignant ascites. A single centre experience
    Satheesh, C. T.
    Patil, S.
    Shashidhara, H. P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites
    Garofalo, A.
    Valle, M.
    Garcia, J.
    Sugarbaker, P. H.
    EJSO, 2006, 32 (06): : 682 - 685
  • [7] Intraperitoneal palliative therapy in refractory malignant ascites
    Castano Carcamo, Mauricio Antonio
    Fletcher Prieto, Angelica Viviana
    REVISTA COLOMBIANA DE CANCEROLOGIA, 2018, 22 (01): : 18 - 38
  • [8] Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer
    Gotlieb, WH
    Feldman, B
    Feldman-Moran, O
    Zmira, N
    Kreizer, D
    Segal, Y
    Elran, E
    Ben-Baruch, G
    GYNECOLOGIC ONCOLOGY, 1998, 71 (03) : 381 - 385
  • [9] A pilot study of combination intraperitoneal recombinant human endostatin and chemotherapy for refractory malignant ascites secondary to ovarian cancer
    Zhao, Jing
    Chen, Xinxiao
    Zhang, Aimu
    Xu, Feng
    Hu, Meilong
    Xie, Congying
    Xue, Shengliu
    MEDICAL ONCOLOGY, 2014, 31 (04)
  • [10] Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review
    Filippo Bellati
    Chiara Napoletano
    Ilary Ruscito
    Maria Pastore
    Milena Pernice
    Morena Antonilli
    Marianna Nuti
    Pierluigi Benedetti Panici
    Investigational New Drugs, 2010, 28 : 887 - 894
12345